PT-141
FDA ApprovedAn FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally rather than on vascular mechanisms. Phase 3 RECONNECT trials demonstrated efficacy.
Bremelanotide · Vyleesi
18 human studies
- Preclinical
- 14%
- Human research
- 51%
Based on 35 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that works centrally in the brain rather than through peripheral vasodilation. It is the first approved treatment that directly increases sexual desire.
How It Works (Simplified)
PT-141 acts through central nervous system pathways to enhance sexual desire:
Crosses the blood-brain barrier and binds MC4R in the hypothalamus, triggering dopamine release in sexual motivation circuits.
Unlike Viagra, PT-141 increases sexual desire itself rather than just physical response - it generates the “wanting” through dopaminergic activation.
MC4R activation also triggers spinal cord pathways that produce genital arousal responses independent of local blood flow mechanisms.
Effects begin 30-60 minutes after injection and peak within 1-4 hours. Short 2.7-hour half-life means effects are time-limited.
Key Research: Kingsberg SA et al. (2019) Phase 3 RECONNECT trials demonstrated significant improvement in FSFI-D and FSDS-DAO scores in premenopausal women with HSDD. PMID:31599840
Important Limitations
- FDA-approved only for premenopausal women with HSDD
- Not approved for male erectile dysfunction despite early trials
- High nausea incidence (40%) limits tolerability
- Transient blood pressure increases require monitoring
- Use limited to 8 doses per month due to cardiovascular effects
- Contraindicated with uncontrolled hypertension or cardiovascular disease
Reported positives
- Effective for sexual desire enhancement in both sexes
- FDA-approved formulation (Vyleesi) validates mechanism
- Effects distinct from PDE5 inhibitors — acts on desire not just function
- Some users report emotional/mood enhancement
Reported negatives
- Nausea is very common and can be severe
- Facial flushing and skin darkening reported
- Effects inconsistent and dose-dependent
- Headaches common side effect
“Unique mechanism targeting desire rather than mechanics. Community discussions span both clinical and research peptide contexts.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| NCT06867835 | Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk Lactating Mother | PT-141 | Phase 4 | Completed | Nov 2025 (date type unverified) |
| NCT06565611 | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity Obesity | PT-141 | Phase 2 | Active | Feb 2025 (date type unverified) |
| NCT05709444 | A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Kidney Disease | PT-141 | Phase 2 | Completed | Apr 2024 (date type unverified) |
| NCT04943068 | A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) Hypoactive Sexual Desire Disorder | PT-141 | Phase 3 | Completed | May 2023 (date type unverified) |
| NCT04179734 | Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Hypoactive Sexual Desire Disorder | PT-141 | Phase 4 | Completed | Oct 2020 (date type unverified) |
| NCT03973047 | Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran Nausea | PT-141 | Phase 1 | Completed | Jul 2019 (date type unverified) |
| NCT02338960 | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Hypoactive Sexual Desire Disorder | PT-141 | Phase 3 | Completed | Aug 2016 (date type unverified) |
| NCT02333071 | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Hypoactive Sexual Desire Disorder | PT-141 | Phase 3 | Completed | Jul 2016 (date type unverified) |
| NCT01382719 | Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder | PT-141 | Phase 2 | Completed | Sep 2012 (date type unverified) |
| NCT00425256 | Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Sexual Arousal Disorder | PT-141 | Phase 2 | Completed | May 2007 (date type unverified) |
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Based on clinical pharmacodynamic studies: effects begin roughly 30-60 minutes after subcutaneous injection. Vyleesi is taken at least 45 minutes before anticipated sexual activity per its FDA labeling.
PMID:14999221Peak effects typically occur within 1-4 hours of administration. Studies showed increased desire and arousal during this window. Nausea (40%) peaks and typically resolves within this period.
PMID:14999221Effects may persist for 4-12 hours in some individuals. Duration is variable. The relatively short half-life means effects are time-limited compared to longer-acting therapies.
Effects generally resolve within 24 hours. PT-141 is used on an as-needed basis (at least 45 minutes before anticipated activity), not daily. Do not use more than once in 24 hours.
PMID:14999221Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
BPC-157
CompatibleDifferent mechanisms with no known interaction. BPC-157's gastroprotective effects may theoretically help with PT-141's nausea, though this is speculative.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms (immune modulation vs melanocortin signaling). No known contraindications.
Semaglutide
CautionBoth can cause nausea. PT-141 commonly causes nausea (40% incidence). GI adverse events may be additive. Monitor tolerability.
Tirzepatide
CautionSimilar caution as semaglutide. Both affect GI function and can cause nausea. Monitor for additive GI effects.
Melanotan-II
AvoidBoth are melanocortin receptor agonists with overlapping activity. PT-141 is derived from Melanotan II. Combining would provide redundant stimulation with increased adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare PT-141
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
Follistatin is an endogenous protein that binds activin and myostatin. Small human AAV gene-transfer studies and trials of an engineered follistatin-based protein do not establish clinical benefit or safety for native follistatin protein administration.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
Compared With
2 comparisonsConditions Studied
4 entries- PT-141 for Erectile Dysfunction PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women but has been studied for erectile dysfunctio…
- PT-141 for Sexual Dysfunction PT-141 was FDA-approved in 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first…
- PT-141 for Low Libido PT-141 addresses low libido through melanocortin-4 receptor activation in brain areas involved in sexual motivation. Unlike hormon…
- PT-141 for Female Sexual Dysfunction PT-141 is specifically FDA-approved for female hypoactive sexual desire disorder, making it one of few pharmacological options for…